Lagociclovir valactate

®

Cat. No.: CAS No.: Molecular Formula: Molecular Weight: Target: Pathway: Storage:	HY-107026 1001670-19-4 $C_{_{19}}H_{_{27}}FN_6O_6$ 454.45 HBV Anti-infection Please store the product under the recommended conditions in the Certificate of Analysis.	$\begin{array}{c} \overset{\mathrm{NH}_2}{\underset{0}{\overset{0}{\overset{0}{\overset{0}{\overset{0}{\overset{0}{\overset{0}{0$
---	--	---

ГҮ				
Lagociclovir valactate is a p	prodrug of Lagociclovir (HY-1484	14). Lagociclovir valac	tate is an orally active	e anti-HBV agent ^[1] .
HBV ^[1]				
woodchucks ^[1] .				(WHV) activity in
Animal Model:	Woodchucks with chronic WHV infection $^{[1]}$			
Dosage: 20 or 60 mg/kg				
Administration:	Oral, daily for 10 weeks			
Result:	Reduced WHV viremia effec	tively and maintained	d WHV DNA at a very lo	ow level.
Animal Model:	Woodchucks ^[1]			
		cic)		
Result:	Average pharmacokinetic par Lagociclovir valactate to heal	rameters for Lagocicle thy and chronically W Healthy	/HV infected woodchu Healthy	ucks ^[1] WHV-infected
	HBV ^[1] Lagociclovir valactate (20 o woodchucks ^[1] . MCE has not independently Animal Model: Dosage: Administration: Result: Animal Model: Dosage: Administration:	HBV ^[1] Lagociclovir valactate (20 or 60 mg/kg; p.o.; daily for 10 we woodchucks ^[1] . MCE has not independently confirmed the accuracy of thes Animal Model: Woodchucks with chronic W Dosage: 20 or 60 mg/kg Administration: Oral, daily for 10 weeks Result: Reduced WHV viremia effect Animal Model: Woodchucks ^[1] Dosage: 10 or 40 mg/kg Administration: Oral (Pharmacokinetic Analys) Result: Average pharmacokinetic parameter Pharmacokineticparameter Pharmacokineticparameter	HBV ^[1] Lagociclovir valactate (20 or 60 mg/kg; p.o.; daily for 10 weeks) shows anti-wood woodchucks ^[1] . MCE has not independently confirmed the accuracy of these methods. They are Animal Model: Woodchucks with chronic WHV infection ^[1] Dosage: 20 or 60 mg/kg Administration: Oral, daily for 10 weeks Result: Reduced WHV viremia effectively and maintained Animal Model: Woodchucks ^[1] Dosage: 10 or 40 mg/kg Administration: Oral (Pharmacokinetic Analysis) Result: Average pharmacokinetic parameters for Lagociclov Lagociclovir valactate to healthy and chronically W Pharmacokineticparameter Healthy woodchucks (n = 4) receiving Lagociclovir valactate at 10	Lagociclovir valactate (20 or 60 mg/kg; p.o.; daily for 10 weeks) shows anti-woodchuck hepatitis virus woodchucks ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Woodchucks with chronic WHV infection ^[1] Dosage: 20 or 60 mg/kg Administration: Oral, daily for 10 weeks Result: Reduced WHV viremia effectively and maintained WHV DNA at a very low Animal Model: Woodchucks ^[1] Dosage: 10 or 40 mg/kg Administration: Oral (Pharmacokinetic Analysis) Result: Average pharmacokinetic parameters for Lagociclovir after oral adminis Lagociclovir valactate to healthy and chronically WHV infected woodchucks (n = 4) receiving Lagociclovir valactate at 10



Product Data Sheet

C _{max} (µM)	0.54 ± 0.14	2.10 ± 1.5	3.50 ± 1.9
T _{max} (h)	4.10 ± 1.0	3.30 ± 1.5	2.90 ± 1.1
AUC _{0-∞} (μM • h/liter)	5.15 ± 1.0	10.50 ± 4.2	20.1 ± 11.3
t _{1/2} (h)	5.44 ± 1.2	4.20 ± 1.6	4.7 ± 0.8

REFERENCES

[1]. Michalak TI, et al. Profound antiviral effect of oral administration of MIV-210 on chronic hepadnaviral infection in a woodchuck model of hepatitis B. Antimicrob Agents Chemother. 2009 Sep;53(9):3803-14.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA